Drug intelligence / Profile preview

miR-148a-3p mimic

Development stage
Preclinical
Modality
RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intrathecal
01

Overview

miR-148a-3p mimic is a synthetic double-stranded RNA oligonucleotide designed to emulate the biological activity of the endogenous microRNA hsa-miR-148a-3p. In the context of multiple myeloma (MM) research, miR-148a-3p has been identified as an oncomiR that is significantly overexpressed in patients and associated with increased tumor cell proliferation. The mimic is primarily utilized as a research tool in gain-of-function studies to demonstrate that elevated levels of miR-148a-3p lead to the post-transcriptional silencing of tumor suppressor genes, including CCDC6, PTEN, SH2B3, and PREX1. By binding to the 3' untranslated regions (UTRs) of these target mRNAs, the mimic induces translational inhibition or mRNA degradation, thereby promoting oncogenic signaling pathways and cellular proliferation. While the mimic serves to elucidate disease mechanisms, therapeutic strategies in MM typically focus on miR-148a-3p inhibitors to counteract these effects.

Other names
microRNA-148a-3p mimicmicroRNA148a-3p mimicmicroRNA 148a-3p mimichsa-miR-148a-3p mimichsa-miR148a-3p mimichsa-miR 148a-3p mimic
02

Targets

CCDC6 (Coiled-coil domain-containing protein 6)PREX1 (P-Rex1 / PREX1)PTEN (Phosphatase and tensin homolog deleted on chromosome ten)SH2B3 (SH2B adapter protein 3)

Beyond the preview

Go deeper on miR-148a-3p mimic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-148a-3p mimic.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call